Abstract
Human mobility drives the spread of many infectious diseases, yet the health impacts of changes in mobility due to new infrastructure development are poorly understood and currently not accounted for in impact assessments. We take a novel quasi-experimental approach to identifying the link between mobility and infectious disease, leveraging historical road upgrades as a proxy for regional human mobility changes. We analyzed how highway paving altered transmission of dengue—a high-burden mosquito-borne disease—via changes in human movement in the Madre de Dios region of Peru. The paving of the Interoceanic Highway through a formerly isolated region of the Amazon in 2009 provided a unique opportunity to quantify the causal impact of road paving on disease transmission. To uncover this relationship, we compared dengue incidence data from healthcare facilities in Madre de Dios near to versus far from the newly paved highway before and after paving, while controlling for observable and unobservable confounding variables (a difference-in-differences causal inference approach). We found that the paving of the highway caused at least an additional 9,826 (95% CI: 8,562–10,684) dengue cases since paving, accounting for 45.2% (95% CI: 39.4%–49.2%) of all dengue cases recorded in the region post highway paving (2009–2022). Our findings demonstrate the impact that infrastructure can have on dengue transmission, likely via its effects on human mobility. As a result, we advocate for future road construction plans in tropical regions to account for potential increases in dengue transmission during impact assessments.
Significance statement Large-scale infrastructure projects are critical for meeting global development goals, but they can also have unintended consequences for local human and environmental health. More evidence attributing human health effects to infrastructure projects is needed to understand how to mitigate these negative health impacts. Our study contributes to this body of knowledge, attributing nearly half of recent dengue cases in Madre de Dios, Peru to the paving of the Interoceanic Highway through the region in 2009. Our results demonstrate the impact that highway construction can have on human health and call for future infrastructure projects through tropical forests to consider infectious disease outcomes in their impact assessments.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
ALS was supported by the Jim and Gaye Pigott Fellowship through the Stanford Interdisciplinary Graduate Fellowship program at Stanford University. AGL is sponsored by Emerge, the Emerging Diseases Epidemiology Research Training grant D43 TW007393 awarded by the Fogarty International Center of the US National Institutes of Health. AJM acknowledges the USDA National Institute of Food and Agriculture (2023-68016-40683) and the National Science Foundation and Fogarty International Center (DEB-2011147; DEB-2339209). LM was supported by the National Science Foundation (DEB-2011147 with Fogarty International Center). EAM was supported by the National Science Foundation (DEB-2011147 with Fogarty International Center), the National Institutes of Health (R35GM133439, R01AI168097, R01AI102918), the Stanford Woods Institute for the Environment, Center for Innovation in Global Health, and King Center on Global Development.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Stanford IRB office determined that this analysis did not qualify as Human Subjects Research as defined in 45 CFR 46.102(e)(5), given the data did not contain any identifiable information.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.